



ASO VISUAL ABSTRACT


## ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation

Caressa Hui, MD<sup>1</sup>, Agnes Ewongwo, MD<sup>1</sup>, Brianna Lau, BS<sup>1</sup>, George Fisher, MD<sup>2</sup>, Daniel Delitto, MD, PhD<sup>2</sup>, George Poultsides, MD, MS<sup>3</sup>, Quoc-Anh Ho, MD<sup>1</sup>, Elham Rahimy, MD<sup>1</sup>, Erqi Pollom, MD, MS<sup>1</sup>, Daniel T. Chang, MD<sup>4</sup>, and Lucas K. Vitzthum, MD, MS<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, Stanford University, Stanford, CA; <sup>2</sup>Department of Medical Oncology, Stanford University, Stanford, CA; <sup>3</sup>Department of Surgical Oncology, Stanford University, Stanford, CA; <sup>4</sup>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

In patients with locally advanced gastric adenocarcinoma without a complete pathologic response to neoadjuvant therapy, 3-year cumulative incidence of locoregional failure

and distant metastases were 8.4 and 41.0%, respectively. Adjuvant locoregional therapy is unlikely to affect survival (<https://doi.org/10.1245/s10434-023-14350-1>).



**FUNDING** D.T.C. received RefleXion research funding and Varian honoraria.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.